Prolonged use of intrauterine contraceptive device as a risk factor for tubo-ovarian abscess

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 6, 2009, Pages 680-684

  Charonis, Georgios ^a,b,c,d   Larsson, Per Göran ^a,b,c  

^a CENTRAL HOSPITAL   (Sweden)

^b UNIVERSITY OF SKÖVDE   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d Department of Obstetrics and Gynecology ^*  (Sweden)

Author keywords

Intrauterine contraceptive device; Pelvic inflammatory disease; Salpingitis; Tubo ovarian abscess

Indexed keywords

COPPER INTRAUTERINE DEVICE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CULTURE; CHLAMYDIA TRACHOMATIS; ENDOMETRITIS; FEMALE; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; NEISSERIA GONORRHOEAE; PRIORITY JOURNAL; PUS; RETROSPECTIVE STUDY; RISK FACTOR; SAFETY; SALPINGITIS; SEXUALLY TRANSMITTED DISEASE; SWEDEN; TUBOOVARIAN ABSCESS; UPPER RESPIRATORY TRACT; UTERINE CERVIX CYTOLOGY; ABSCESS; ADNEXA DISEASE; MIDDLE AGED; PELVIC INFLAMMATORY DISEASE; PELVIS; TIME;

ABSCESS; ADNEXAL DISEASES; ADULT; FEMALE; HUMANS; INTRAUTERINE DEVICES; MIDDLE AGED; PELVIC INFLAMMATORY DISEASE; PELVIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 66149155042     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340902893678     Document Type: Article

References (13)

1. d'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception. 2007;75:2-7.
2. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356:1013-9.
3. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339:785-8.
4. Beerthuizen RJ. Pelvic inflammatory disease in intrauterine device users. Eur J Contracept Reprod Health Care. 1996;1: 237-3.
5. United Nations Development Programme, United Nations Population Fund, World Health Organization and World Bank, Special Programme of Research, Development and Research Training in Human Reproduction Long-term reversible contraception. Twelve years of experience with the TCu380A and TCu220C. Contraception. 1997;56:341-52.
6. Information från Läkemedelsverket. Antinkonception - be-handlingsrekommendation [Information from the Swedish Medical Products Agency. Contraception - recommendation of treatment methods] 2005;7:7-88 (in Swedish).
7. Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55:1-94.
8. Eschenbach DA, Wölner-Hanssen P, Hawes SE, Pavletic A, Paavonen J, Holmes KK. Acute pelvic inflammatory disease: associations of clinical and laboratory findings with laparoscopic findings. Obstet Gynecol. 1997;89:184-92.
9. Morris JA, Gardner MJ. Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed). 1988;296:1313-6.
10. Patai K, Berenyi M, Sipos M, Nozal B. Characterization of calcified deposits on contraceptive intrauterine devices. Contraception. 1998;58:305-8.
11. Viberga I, Odlind V, Berglund L. "Older" age is a risk factor for pelvic inflammatory disease in intrauterine device users. Acta Obstet Gynecol Scand. 2005;84:1202-7.
12. Hebb JK, Cohen CR, Astete SG, Bukusi EA, Totten PA. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis. 2004;190:2109-20.
13. Charonis G, Larsson P-G. Use of pH/whiff test or QuickVue Advanced® pH and Amines test for the diagnosis of bacterial vaginosis and prevention of postabortion pelvic inflammatory disease. Acta Obstet Gynecol Scand. 2006;85:837-3.